There have been ongoing difficulties that patients are having with accessing subcutaneous tocilizumab.


The pharmaceutical company Roche maintains that there should be enough supply for current patients on subcutaneous tocilizumab and patients should ask their pharmacists to be in touch with the wholesalers.

Roche say that stock is being released to wholesalers on a weekly basis.


This is distressing and time-consuming for patients, families, and prescribers. Please know that the Australian Rheumatology Society is working hard for members and their patients on this issue.

The most recent communication from Roche can be found on our website here.

This post will be updated as more information becomes available.